2 employees
Fabrus identifies and develops functional therapeutic monoclonal antibodies to challenging cell surface targets like GPCRs and ion channels.
2007
$2M
from 1 investors over 1 rounds
Fabrus raised $2M on November 4, 2010
Investors: OPKO Health, Inc.